Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study from Stanford is evaluating CD19/CD22 CAR T cells with or without NKTR-255 in adults with recurrent or refractory B-cell malignancies; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19/CD22 CAR-T cells
• NKTR-255 (NKTR-255)

Snippet

Sponsor: Stanford University | Conditions: B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Status: ACTIVE_NOT_RECRUITING